Brief: Quantum Genomics Updates on Phase III Hypertension Study
13/07/2020 07:12
July 13 (Reuters) - Quantum Genomics SA ALQGC.PA :
* ANNOUNCES THE RECRUITMENT OF THE FIRST PATIENT IN THE
FRESH
STUDY, ITS PIVOTAL PHASE III STUDY IN DIFFICULT TO TREAT /
RESISTANT HYPERTENSION
* STUDY IS CARRIED OUT JOINTLY WITH THE BIOLAB SANUS
PHARMACEUTICAL LABORATORY, QUANTUM GENOMICS PARTNER FOR LATIN
AMERICA
Source text for Eikon: ID:nACT64262
Further company coverage: ALQGC.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Quantum Genomics SA
See all newsBrief: Quantum Genomics Announces Resumption Of Discussions With HealthTech, Terminates Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics Enters Into Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics To Reduce Staff; Jean-Philippe Milon Becomes President and CEO
Brief: Quantum Genomics In Talks For New Strategic Project
Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study